Literature DB >> 8811340

Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS.

G Scarlatti1, T Leitner, V Hodara, M Jansson, A Karlsson, J Wahlberg, P Rossi, M Uhlén, E M Fenyö, J Albert.   

Abstract

A majority of human immunodeficiency virus type 1 (HIV-1) infected individuals display a rapid loss of CD4+ lymphocytes with fast progression towards overt acquired immunodeficiency syndrome (AIDS). However, a small proportion of individuals infected by HIV-1 remain immunologically intact for many years. In order to identify factors that might influence the pathogenesis of HIV-1 infection, 21 Italian mothers and 11 Swedish homosexual men were studied for the presence of autologous neutralizing antibodies in serum, biological phenotype of virus isolates and envelope variable region 3 (V3) sequences. The results were compared to the risk of mother-to-child transmission and progression of the disease. The presence of a neutralizing antibody response to the autologous virus as well as a virus with slow replicative capacity were linked both to low risk of mother-to-child transmission and non-progression of the disease. Patients whose peripheral blood mononuclear cells contained a mutation in the tip of the V3 loop (Arg318 to serine, lysine or leucine) significantly more often had neutralizing antibodies to autologous virus isolates containing arginine at this position. Thus, it appears that the interplay and balance between neutralizing antibody response of the host and the biological phenotype of HIV-1 strongly influence pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811340     DOI: 10.1016/0165-2478(96)02550-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Authors:  Madhumita Mahalanabis; Pushpa Jayaraman; Toshiyuki Miura; Florencia Pereyra; E Michael Chester; Barbra Richardson; Bruce Walker; Nancy L Haigwood
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

3.  Dynamics of cytotoxic T-lymphocyte exhaustion.

Authors:  D Wodarz; P Klenerman; M A Nowak
Journal:  Proc Biol Sci       Date:  1998-02-07       Impact factor: 5.349

4.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

6.  Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.

Authors:  Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

7.  Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection.

Authors:  Paul S Wikramaratna; José Lourenço; Paul Klenerman; Oliver G Pybus; Sunetra Gupta
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

Review 8.  Neutralization-Enhancing RF Antibodies for HIV Vaccines.

Authors:  Konstantin V Suslov
Journal:  Front Immunol       Date:  2014-12-16       Impact factor: 7.561

9.  Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.

Authors:  Elizabeth Fink; Katherine Fuller; Brian Agan; Edward A Berger; Andrew Saphire; Gerald V Quinnan; John H Elder
Journal:  AIDS Res Hum Retroviruses       Date:  2016-11-21       Impact factor: 2.205

10.  Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Authors:  C Spenlehauer; S Saragosti; H J Fleury; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.